oxotremorine has been researched along with Parkinson Disease in 8 studies
Oxotremorine: A non-hydrolyzed muscarinic agonist used as a research tool.
Parkinson Disease: A progressive, degenerative neurologic disease characterized by a TREMOR that is maximal at rest, retropulsion (i.e. a tendency to fall backwards), rigidity, stooped posture, slowness of voluntary movements, and a masklike facial expression. Pathologic features include loss of melanin containing neurons in the substantia nigra and other pigmented nuclei of the brainstem. LEWY BODIES are present in the substantia nigra and locus coeruleus but may also be found in a related condition (LEWY BODY DISEASE, DIFFUSE) characterized by dementia in combination with varying degrees of parkinsonism. (Adams et al., Principles of Neurology, 6th ed, p1059, pp1067-75)
| Excerpt | Relevance | Reference |
|---|---|---|
| "Parkinson disease is a neurodegenerative disorder whose symptoms are caused by the loss of dopaminergic neurons innervating the striatum." | 1.33 | RGS4-dependent attenuation of M4 autoreceptor function in striatal cholinergic interneurons following dopamine depletion. ( Chen, S; Ding, J; Ebert, PJ; Goldberg, JA; Guzman, JN; Hamm, HE; Levitt, P; Surmeier, DJ; Tkatch, T; Wilson, CJ, 2006) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 6 (75.00) | 18.7374 |
| 1990's | 1 (12.50) | 18.2507 |
| 2000's | 1 (12.50) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ding, J | 1 |
| Guzman, JN | 1 |
| Tkatch, T | 1 |
| Chen, S | 1 |
| Goldberg, JA | 1 |
| Ebert, PJ | 1 |
| Levitt, P | 1 |
| Wilson, CJ | 1 |
| Hamm, HE | 1 |
| Surmeier, DJ | 1 |
| Kehr, W | 1 |
| Kinoshita, H | 1 |
| Hasegawa, T | 1 |
| Katsumata, Y | 1 |
| Kameyama, T | 1 |
| Yamamoto, I | 1 |
| Nabeshima, T | 1 |
| Tang, LC | 1 |
| Cotzias, GC | 1 |
| Brossi, A | 1 |
| Pool, W | 1 |
| Sheppard, H | 1 |
| Burns, JJ | 1 |
| Kaiser, A | 1 |
| Bigler, R | 1 |
| Bartholini, G | 1 |
| Pletscher, A | 1 |
| Brown, DM | 1 |
| Hughes, BO | 1 |
| Marsden, CD | 1 |
| Meadows, JC | 1 |
| Spicer, B | 1 |
| Borgman, RJ | 1 |
| Mcphillips, JJ | 1 |
| Stitzel, RE | 1 |
| Goodman, IJ | 1 |
| Pálosi, E | 1 |
| Szporny, L | 1 |
1 trial available for oxotremorine and Parkinson Disease
| Article | Year |
|---|---|
Some initial animal and human pharmacological studies with benapryzine (BRL 1288).
Topics: Acetylcholine; Aged; Animals; Antiparkinson Agents; Benzilates; Clinical Trials as Topic; Dose-Respo | 1973 |
7 other studies available for oxotremorine and Parkinson Disease
| Article | Year |
|---|---|
RGS4-dependent attenuation of M4 autoreceptor function in striatal cholinergic interneurons following dopamine depletion.
Topics: Acetylcholine; Action Potentials; Animals; Autoreceptors; Calcium Channels; Cell Communication; Corp | 2006 |
[Drug therapy of Parkinson disease and parkinson disease-like symptoms].
Topics: Adenylyl Cyclases; Animals; Aromatic-L-Amino-Acid Decarboxylases; Biperiden; Brain; Catechol O-Methy | 1981 |
Effect of dizocilpine (MK-801) on the catalepsy induced by delta 9-tetrahydrocannabinol in mice.
Topics: Acetylcholine; Animals; Catalepsy; Disease Models, Animal; Dizocilpine Maleate; Dopamine; Dronabinol | 1994 |
Modification of the actions of some neuroactive drugs by growth hormone.
Topics: Animals; Apomorphine; Behavior, Animal; Dihydroxyphenylalanine; Dopamine; Drug Synergism; Growth Hor | 1976 |
L-DOPA: chemical modifications and biological evaluation.
Topics: Animals; Antiparkinson Agents; Blepharoptosis; Catatonia; Disease Models, Animal; Humans; Hypothermi | 1974 |
Synthesis and pharmacology of centrally acting dopamine derivatives qnd analogs in relation to parkinson's disease.
Topics: Acetylation; Alkylation; Animals; Body Temperature; Chemical Phenomena; Chemistry; Dopamine; Hydroly | 1973 |
Effect of gamma-hydroxybutyric acid on tremor induced oxotremorin.
Topics: Animals; Atropine; Brain Chemistry; Disease Models, Animal; Drug Antagonism; Drug Synergism; Female; | 1972 |